Drug development is one of the most complex and challenging processes in modern science. Bringing a new medicine from an initial scientific concept to a product that can be prescribed to patients requires years of research, significant investment, and collaboration across multiple disciplines.

While the drug development process is often presented as a simple sequence of discovery, development, clinical trials, and approval, the reality is far more complex. Success requires continuous learning, evidence-based decision making, and the ability to navigate scientific, clinical, regulatory, and commercial challenges along the way.

In this article, we explore how the drug development process works, the key stages involved, why so many drug candidates fail, and the factors that increase the likelihood of success.

 

Understanding the Drug Development Process

At a high level, the drug development process can be divided into several stages:

1. Drug discovery and target identification
2. Preclinical development
3. Clinical development
4. Regulatory review and approval
5. Commercialisation
6. Post-market monitoring and lifecycle management

 

Textbook diagrams often portray these stages as a straightforward, linear pathway. However, as highlighted during our trainer interview, the reality is much closer to a “spaghetti junction” than a straight line. Drug development is highly dynamic, with multiple iterations, feedback loops, and decision points throughout the journey.

The specific pathway will also vary depending on:

• The disease being targeted
• The type of therapy being developed
• The available scientific knowledge
• Regulatory requirements
• Commercial considerations

 

Regardless of the complexity, the ultimate goal remains the same: delivering safe and effective treatments that address unmet patient needs.

 

Stage 1: Drug Discovery and Target Identification

Every drug development programme begins with understanding a disease.

Researchers seek to identify:

• The biological mechanisms driving the disease
• Potential therapeutic targets
• Opportunities to intervene with a medicine

 

A target may be:

• A protein
• A receptor
• A gene
• A signalling pathway
• A cellular process

 

The more researchers understand the underlying disease biology, the greater their chances of identifying a meaningful therapeutic target. According to the interview, success begins with unravelling the molecular underpinnings of disease and using that knowledge to identify the most appropriate target, drug, and therapeutic modality.

 

Why Most Drug Discovery Projects Fail

Drug discovery is characterised by exceptionally high failure rates.

Only a tiny fraction of initial ideas ultimately become approved medicines. The transcript notes that between one in 10,000 and one in 30,000 therapeutic concepts may eventually progress through the full development pathway.

Many projects fail because:

• The target is not sufficiently validated
• Disease biology is poorly understood
• The drug lacks efficacy
• Toxicity concerns emerge
• Commercial viability is limited

 

The highest attrition rates typically occur during the earliest stages of discovery and target validation.

 

Stage 2: Preclinical Development

Once a promising candidate has been identified, it enters preclinical development.

This phase aims to answer critical questions:

• Does the drug work?
• Is it safe?
• What dose should be used?
• How does it behave in the body?

 

Preclinical studies typically involve:

• Laboratory experiments
• Cell-based studies
• Animal studies
• Toxicology assessments
• Pharmacology investigations

 

The purpose is to generate sufficient evidence to justify testing the drug in humans.

 

Building the Foundation for Clinical Success

One of the most important messages from the trainer interview is that early-stage decisions significantly influence later success.

The quality of the science conducted during discovery and preclinical development shapes every subsequent stage. Poor decisions made early often become expensive failures later.

Successful programmes focus heavily on:

• Translational science
• Mechanism of action
• Biomarker development
• Pharmacology
• Patient relevance

 

These activities create the evidence base needed to move confidently into clinical development.

 

The Growing Importance of Biomarkers

Modern drug development increasingly relies on biomarkers.

Biomarkers are measurable indicators that help researchers understand:

• Whether a drug is working
• Which patients may benefit
• How the disease is progressing
• Whether safety concerns are emerging

 

The interview identified biomarker strategy as one of the most important determinants of success during development. Researchers must consider biomarkers from the earliest laboratory studies through to clinical trials and eventual patient use.

Examples may include:

• Genetic markers
• Protein expression levels
• Imaging results
• Pharmacodynamic measurements
• Disease progression indicators

 

An effective biomarker strategy improves decision making throughout the development lifecycle.

 

Stage 3: Clinical Development

Clinical development begins once sufficient preclinical evidence has been generated.

At this point, the focus shifts to testing the therapy in humans.

Clinical development generally occurs in three main phases:

 

Phase I: Safety First

Phase I trials typically involve a small number of participants.

The objectives are to:

• Assess safety
• Evaluate tolerability
• Understand pharmacokinetics
• Determine appropriate dose ranges

The primary question is simple: can the therapy be administered safely?

 

Phase II: Exploring Efficacy

Phase II studies expand into larger patient populations.

Researchers investigate:

• Clinical activity
• Dose optimisation
• Additional safety data
• Biomarker responses

 

At this stage, developers begin assessing whether the therapy is producing meaningful clinical benefits.

 

Phase III: Confirmatory Studies

Phase III trials are designed to provide the evidence required for regulatory approval.

These studies often involve:

• Large patient populations
• Multiple study sites
• Comparisons with existing standards of care
• Long-term safety assessments

Success in Phase III provides the foundation for regulatory submissions.

 

Why Clinical Trials Fail

Clinical development remains one of the most challenging stages of the drug development process.

According to the interview, successful clinical trials require not only the right drug but also the right patients and the right biomarkers.

Common causes of failure include:

 

Incomplete Understanding of Disease Biology

Many diseases are highly complex and heterogeneous.

Patients who appear to have the same condition may respond very differently to treatment.

 

Poor Patient Selection

If a therapy is tested in the wrong patient population, genuine benefits may be difficult to detect.

 

Weak Biomarker Strategies

Without reliable biomarkers, researchers may struggle to understand whether a drug is working or how it should be developed further.

 

Inadequate Clinical Endpoints

Choosing inappropriate outcome measures can undermine even scientifically promising programmes.

 

The Critical Role of Clinical Trial Design

Clinical trial design is one of the most important success factors in drug development.

Well-designed studies help:

• Demonstrate safety
• Show efficacy
• Support regulatory approval
• Improve commercial viability
• Accelerate patient access

 

The interview highlighted the growing use of innovative trial approaches such as adaptive trial designs and investigator-initiated studies, which can provide greater flexibility and efficiency compared with traditional clinical trial models.

The best trial designs are built around:

• Strong scientific rationale
• Clear patient selection criteria
• Meaningful biomarkers
• Relevant clinical endpoints
• Appropriate statistical methodologies

 

Stage 4: Regulatory Review and Approval

Once clinical development has generated sufficient evidence, sponsors submit data to regulatory authorities.

The specific pathway varies by region, but regulators generally evaluate:

• Quality
• Safety
• Efficacy
• Manufacturing controls
• Benefit-risk profile

 

Examples of major regulatory authorities include:

• European Medicines Agency
• U.S. Food and Drug Administration
• Medicines and Healthcare products Regulatory Agency

 

The goal is to determine whether the benefits of the therapy outweigh its risks for patients.

For therapies addressing serious unmet medical needs, accelerated pathways may be available, allowing faster access to potentially life-saving treatments. The interview noted that trial design can play an important role in supporting accelerated regulatory pathways.

 

Stage 5: Commercialisation

Regulatory approval is a major milestone, but it is not the end of the process.

Following approval, organisations must:

• Scale manufacturing
• Manage supply chains
• Educate healthcare professionals
• Support patient access
• Monitor product performance

 

Commercial success depends not only on scientific achievement but also on effective execution across multiple functions.

 

Stage 6: Post-Market Surveillance and Lifecycle Management

After launch, medicines continue to be monitored.

Post-market activities include:

• Pharmacovigilance
• Safety reporting
• Risk management
• Real-world evidence collection
• Additional clinical studies

 

Companies may also pursue:

• New indications
• Expanded patient populations
• New formulations
• Combination strategies

 

Drug development therefore continues long after initial approval.

 

Why Portfolio Management Matters in Drug Development

Because failure rates are so high, organisations cannot rely on a single programme.

Portfolio management helps companies balance:

• Risk
• Resources
• Timelines
• Scientific opportunities

 

As discussed during the interview, successful organisations build portfolios with multiple options and clear decision-making frameworks to accommodate inevitable failures and changing circumstances.

This includes:

• Go/no-go decision points
• Portfolio diversification
• External innovation partnerships
• Licensing opportunities
• Mergers and acquisitions
• Strategic collaborations

 

Strong portfolio management enables organisations to maximise long-term value while continuing to deliver innovation.

 

The Future of the Drug Development Process

Drug development is evolving rapidly.

Several trends are reshaping the industry:

• Precision medicine
• Advanced biologics
• Cell and gene therapies
• Artificial intelligence
• Biomarker-driven development
• Adaptive clinical trial designs
• Real-world evidence

 

At the same time, organisations are placing greater emphasis on advanced due diligence and proactive risk assessment to improve decision making. The interview described a shift from analysing why programmes failed after the fact to conducting “pre-mortem” assessments that identify potential challenges before they occur.

 

Conclusion

The drug development process is far more than a linear progression from laboratory discovery to regulatory approval.

It is a complex, multidisciplinary journey involving scientific discovery, preclinical research, clinical development, regulatory strategy, portfolio management, and continuous learning.

While most drug candidates never reach patients, organisations that invest in strong science, robust biomarker strategies, thoughtful clinical trial design, and effective decision making significantly improve their chances of success.

Ultimately, every stage of the process serves a single purpose: delivering safe, effective medicines that address unmet patient needs and improve lives.

🚀 Ready to Advance Your Skills in Drug Development?

Whether you’re entering the field, managing a portfolio, or navigating complex biologics, Educo Life Sciences offers practical, expert-led training to support your growth.

👉 Explore Gareth’s Courses:

Pharmacology Essentials Training: Understanding Pharmacology in Drug Development

Mastering Development and Regulatory Strategies in Cell Therapy

Pharmaceutical Portfolio Strategies: Governance and Portfolio Management

 

 

Interview with Educo Life Sciences Expert, Gareth Willis

Gareth Willis is an experienced biopharmaceutical R&D professional, drug hunter and global project lead with 10+ years of leadership in project/program management, portfolio governance and scientific strategy. He has a successful record of progressing complex, multi-million-dollar drug development programs through internal and external initiatives. He has furthered his practical experience in both Europe and the US, in clinical, pharmaceutical, VC and academic environments facilitating the preclinical -> clinical transition of novel medicinal products. Relevant former roles and institutions include Principal Investigator/Lecturer (Harvard Medical School & Boston Children’s Hospital), Fellow and Project Lead (Vertex Pharmaceuticals), Global Project Lead (Boehringer-Ingelheim) and Asset and Scientific Evolution Lead (invoX Pharma).

In his current role(s), he leads a dynamic cross-functional global team that pushes scientific and drug development boundaries, developing novel medicinal products and drug-device combinations (modality and indication agnostic), to meet unmet patient needs worldwide. He has a wealth of experience in establishing agile governance frameworks to oversee a diverse clinical and preclinical portfolio. Notably, he has extensive experience in translational biomarker strategies, indication expansions (repurposing), and effective tech-transfer for up-scale bioprocessing of biologics.

Overseeing a global team, Gareth has a proven track record in increasing pipeline visibility and executing external collaborations. He has bridged the gap between preclinical -> clinical, implementing novel ‘first-4-patient’ initiatives, such as 5’R research frameworks, relevant clinical biomarker strategies and optimising human dose prediction models to enhance the probability of success of medicinal products.